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Human mesenchymal stem cells (hMSC) are relevant cell therapy products for autologous and allogeneic 
therapies. To deliver the required cell numbers and doses to therapy, scaling up production and purification 
processes (at least to the liter-scale) while ensuring high purity, viability and maintaining cells’ critical quality 
attributes (CQA) and functionality is essential. 
 
Therefore, the aim of this work was to prove scalability of an integrated streamlined bioprocess compatible with 
current good manufacturing practices (cGMP) comprised by cell expansion, harvesting, volume reduction and 
washing unit operations using human mesenchymal stem cells (hMSC) isolated from bone marrow (BM-MSC) 
and adipose tissues (AT-MSC). Single-use technologies were adopted at different steps of the manufacturing 
workflow  to support process integration and scale-up. 
 
BM-MSC and AT-MSC expansion and harvesting steps were scaled-up from spinner flasks to 2 L single-use 
stirred tank bioreactor using synthetic microcarriers and xeno-free medium, ensuring high cellular volumetric 
productivities (50 x 106 cell.L-1.day-1), expansion factors (14 - 16 fold) and cell recovery yields (>80%).  
 
For the volume reduction and washing steps, flat sheet cassettes (FSC) and hollow fiber cartridges (HF) were 
compared showing a fairly linear scale-up, with a need to slightly decrease the permeate flux (30 - 50 LMH, 
respectively) to maximize cell recovery yield. Nonetheless, FSC performed better allowing recovering 18% more 
cells after a volume reduction factor of 50 without compromising cell’s CQA of viability, identity and 
differentiation potential.  
 
“Omic” tools in combination with standard analytical assays allow for a better cell characterization, increasing 
product and process understanding and are thus fundamental for process development. Thus, alongside the 
standard quality assays for evaluating hMSC’s CQA, a proteomics workflow based on mass spectrometry tools 
was established to characterize the impact of processing on hMSC’ CQA. Overall, through sensitivity, 
robustness and throughput, this type of workflow provided the identification of specific signatures of the final 
product. Therefore, it proves to be essential to understand the cells’ final quality as well as to evaluate the 
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